Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy

Clin Ther. 2007;29 Suppl A:S17-8. doi: 10.1016/s0149-2918(07)80122-6.
No abstract available

MeSH terms

  • Clinical Trials as Topic
  • Fabry Disease / drug therapy*
  • Humans
  • Isoenzymes / therapeutic use*
  • Patient Education as Topic
  • Treatment Outcome
  • alpha-Galactosidase / physiology
  • alpha-Galactosidase / therapeutic use*

Substances

  • Isoenzymes
  • alpha-Galactosidase
  • agalsidase beta